Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Landos Biopharma, Inc.

http://landosbiopharma.com/

Latest From Landos Biopharma, Inc.

Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk

Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.

Deals Business Strategies

Perceptive And Xontogeny’s Second VC Fund Brings In $515m

The strategy for both funds is to back companies with a preclinical drug candidate that can be advanced through clinical proof-of-concept with a mid-sized series A round. 

Financing StartUps and SMEs

Finance Watch: Ten IPOs In Three Days Raise $1.9bn

IPO Edition: Sana leads the group with a $587.5m initial public offering, while Immunocore and Bolt follow with $200m-plus IPOs. The 10 newly public companies generated a 43.3% average return on 8 Feb.

Financing Business Strategies

Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs

Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment. 

Financing Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Digital Health
  • Pharmaceuticals
UsernamePublicRestriction

Register